Effects of E-Tonus in Moderate Parkinson's Disease (ETMOPARK)
A Randomized, Double-blind, Sham-controlled, Crossover, Pilot Clinical Investigation, Evaluating the Short-term Effects of E-Tonus, a Wearable Electromagnetic Device, on Motor Symptoms in Adult Participants With Moderate Parkinson's Disease
The goal of this clinical trial is to evaluate the short-term effect of E-Tonus, a wrist-worn device that gives off a low-intensity pulsed electromagnetic field, on functional mobility in adults with moderate Parkinson's disease. It will also learn about the short-term safety profile of E-Tonus.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Senior Clinical Project Manager
- 電話番号:+33624358886
- メール:clinical@brainandmind.fr
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Adults aged 50-75 years;
- Parkinson's disease (MDS diagnostic criteria)Hoehn & Yahr stage II to II.5 confirmed in the ON medication state;
- At least one of the following MDS-UPDRS criteria must be met, reflecting the presence of clinically meaningful gait or balance impairment but still able to walk unaided:
- MDS-UPDRS Gait (item 3.10) score = 2, OR
- Freezing of gait (item 3.11) score ranging from 1 to 2, OR
- Postural instability (item 3.12) score ranging from 1 to 2, OR
- Walking & Balance (item 2.12) score = 2, OR
- Freezing (item 2.13) score ranging from 1 to 2;
- Stable dopaminergic therapy ≥4 weeks;
- Predictable ON-state duration ≥2 consecutive hours.
Exclusion Criteria:
- Severe axial motor impairment (pre-specified items rated 3 or 4) or investigator-judged fall/safety risk;
- Pregnancy;
- Electromagnetic hypersensitivity;
- Postural hypotension, musculoskeletal, or vestibular disorders affecting balance;
- Uncontrolled cardiac, pulmonary, major neurological, or metabolic disease;
- Cognitive impairment (MoCA ≤22);
- Implanted active medical device (e.g., DBS, pacemaker) or metal implant/tattoo at the wrist application site;
- History of radial nerve injury on the device-bearing arm;
- Legally protected vulnerable adults.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:4倍
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Active E-Tonus
Participants wear E-Tonus on the wrist in the active condition, emitting low-frequency, low-intensity pulsed electromagnetic field stimulation, for approximately 30 minutes. In this crossover study, all participants receive both the active and sham conditions during a single study visit, in a randomized order, separated by a 30-minute washout period. Assessments are performed in the ON medication state. |
Personal, portable, wrist-worn, non-invasive Class IIa electromagnetic stimulation device manufactured by A.F. Genese. It emits a low-frequency, low-intensity pulsed electromagnetic field with a controlled pulse width, delivering peripheral transcutaneous stimulation at the wrist. Used once, for approximately 30 minutes, during a single study visit, in addition to the participant's usual Parkinson's disease medication. The same wrist-worn device in a sham configuration that emits no electromagnetic field. It is visually and physically indistinguishable from the active device, so that participants and investigators remain blinded. Used once, for approximately 30 minutes, during a single study visit. |
|
偽コンパレータ:Sham E-Tonus
Participants wear E-Tonus on the wrist in the sham condition, with no stimulation emitted, for approximately 30 minutes. The sham device is visually and physically indistinguishable from the active device. In this crossover study, all participants receive both the active and sham conditions during a single study visit, in a randomized order, separated by a 30-minute washout period. Assessments are performed in the ON medication state. |
Personal, portable, wrist-worn, non-invasive Class IIa electromagnetic stimulation device manufactured by A.F. Genese. It emits a low-frequency, low-intensity pulsed electromagnetic field with a controlled pulse width, delivering peripheral transcutaneous stimulation at the wrist. Used once, for approximately 30 minutes, during a single study visit, in addition to the participant's usual Parkinson's disease medication. The same wrist-worn device in a sham configuration that emits no electromagnetic field. It is visually and physically indistinguishable from the active device, so that participants and investigators remain blinded. Used once, for approximately 30 minutes, during a single study visit. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in instrumented Timed Up-and-Go (iTUG) 7-meter total task time: active vs. sham E-Tonus
時間枠:Baseline (before each device condition) and end-of-period (after approximately 30 minutes of device use), for each of the 2 device conditions within a single study visit (Day 1)
|
The iTUG test measures the time (in seconds) a participant needs to stand up from a chair, walk 7 meters, turn around, walk back and sit down again, from the start of the sit-to-stand transition to the end of the stand-to-sit transition. It is instrumented with an accelerometer. Two trials are performed at each time point and averaged. For each device condition (active and sham), the change from baseline to end-of-period is calculated. The outcome is the difference between active and sham conditions in this change. A greater reduction in time indicates better functional mobility. |
Baseline (before each device condition) and end-of-period (after approximately 30 minutes of device use), for each of the 2 device conditions within a single study visit (Day 1)
|
|
Incidence, severity, seriousness and relatedness of adverse events (AEs) and adverse device effects (ADEs)
時間枠:From the start of the first device application (Day 1) through 48 hours after the last device application
|
Number of participants with adverse events and adverse device effects, described by severity (mild, moderate, severe), seriousness (serious or non-serious) and relationship to the device as assessed by the investigator, by device condition (active and sham). |
From the start of the first device application (Day 1) through 48 hours after the last device application
|
協力者と研究者
捜査官
捜査官
- 主任研究者:David DEVOS, Professor Neurologist、Service de Neurologie B : Neurologie vasculaire CHU de Lille - Hôpital Roger Salengro rue Emile Laine 59000 LILLE
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- BM2601-AFGE01
- IDRCB N° 2026-A01795-46 (その他の識別子:ANSM (French National Agency for Medicines and Health Products Safety))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
There is no plan to share individual participant data. This is a small pilot investigation (40 participants), and the data are collected under French and European data protection regulations (GDPR), with participant consent limited to the purposes of this study. Aggregate results will be made available through scientific publication.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。